Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Key facts
- Who runs it
- Kirby Institute
- Where
- Australia5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- Sept 2026
- Expected to end
- Mar 2027
- Type of study
- Interventional
- Treatments tested
- 12 weeks of weekly subcutaneous semaglutide injection
- Record updated
- 26 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Has provided voluntary, written informed consent
- Aged 18 years or older
- Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria)
- Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine
- Willing and able to comply with study procedures and follow-up visits
- People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end
Who cannot take part
- Currently taking a GLP-1 receptor agonist
- Uncontrolled medical or psychiatric conditions that may interfere with participation
- Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information
- History of pancreatitis
- History of medullary thyroid cancer
- Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data
- Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c >6.5 at screening)
- Body mass index less than 22 kg/m2
- Current enrolment in another interventional trial
- Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy
- Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures
- Currently experiencing psychosis or current active suicidality
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.
The group in the trial
- Adults with methamphetamine use disorderTreatment being tested
12 weeks of subcutaneous semaglutide administered once weekly
Treatment: 12 weeks of weekly subcutaneous semaglutide injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 June 2026